Investment: Should you invest in... pharmaceutical companies?

the pharmaceuticals sector has been a source of strong growth, despite the potentially high-risk nature of a business heavily dependent on research and development of new products, and patent protection. The more mature business of chemicals manufacture has also been largely out of favour.

Glenn Meyer of Pavilion Asset Management says: "The two sectors seem to act in opposition. Pharmaceuticals are generally growth stocks and chemical companies tend to be highly cyclical. Pharmaceuticals have a much clearer and longer flow of earnings, and the chemical sector moves in line with the world economy and is much more volatile."

Jeremy Batstone of NatWest Stockbrokers has a different focus."Pharmaceuticals have been very volatile and the sector has tended to lag the market," he says. "People are looking more for value as the economy has improved, away from more defensive growth areas like pharmaceuticals."

Mark Mathias, head of investment funds at Rea Brothers Investment Management, agrees the sector's long-term growth potential is undisputed. Mathias, whose firm runs two specialist pharmaceutical funds, says: "There is the trend to ageing populations in the OECD countries, with the highest proportion of lifetime healthcare expenditure coming in the last two years of life, underpinned by the significant increase in healthcare research expenditure. At the same time, the OECD governments are trying to rein in the cost of government-subsidised healthcare and the way you do that is to spend more on drugs to keep people out of hospital."

North America's political debate about state-funded medical programmes has added to the uncertainty, says Nigel Thomas, manager of ABN Amro's UK Growth Fund. "Proposed legislation in Medicare reform will limit spending on outpatient drug costs for elderly people who account for over 30 per cent of US outpatient drug spending and this will affect pharmaceutical companies - the FT suggests it would impact earnings by between 10 and 15 per cent."

Thomas says the plans will probably not come to fruition but the debate is affecting share prices. "It is a political hot potato but given the Republican position in Congress, we are not so sure it will be enacted."

Size is also going to be a key element in future corporate earnings. "When it comes down to it, healthcare is not an optional expenditure and the amounts spent on it are going to rise," adds Mathias.

"There is very good long-term earnings visibility in the pharmaceutical sector andmergers of large companies. You can sell the same drugs into different markets, and IT helps keep control in multinational companies."

Batstone says: "There is still a lot of scope for mergers and acquisitions in the pharmaceutical sector. Critical mass is the key force driving consolidation because of the large spend on R&D. The quicker you can develop a new drug from scratch, the longer you will have the benefit of its patent protection, but without the scale you haven't got the size or funds for research."

Every major player is in the frame. "SmithKline Beecham is mentioned on a fairly regular basis but Glaxo Wellcome is also rumoured to be looking at an overseas tie-up," he adds.

Glenn Meyer says: "The UK chemical sector has underperformed the market, but overseas firms seem to value UK chemical companies more highly than the market does."

Stock selection is the key. "Concentrate on chemical sector stocks which focus on profitable areas, such as BTP, which constantly refreshes its portfolio," he says. "Avoid larger companies, which tend to underperform the market."

There is scope for the active share trader. Meyer adds: "ICI has been a relatively poor performer for a long time, but with short periods of outperformance, so timing is everything. Look at manufacturers of industrial chemicals. The problem here is that you very quickly reach overcapacity and have a fairly low return on capital."

By contrast, the bulk of investor interest in the drugs sector is focused on the largest stocks. Nigel Thomas says: "There aren't that many pure pharmaceutical companies below pounds 1bn in size. Shire Pharmaceuticals and Medeva, with Galen in Ireland, are the only mid-sized ones and once below a certain size they are largely bio-techs, of which we like Celltech and Phytopharm."

Jeremy Batstone adds: "There are a lot of stocks in the sector relatively cheap, with the possible exception of AstraZeneca. Glaxo Wellcome still looks good value at around pounds 19. We would suggest it could get up to maybe pounds 21.50 or pounds 22 in the short to medium term."

Another key player in the sector is SmithKline Beecham, where investors were holding off until the US Food & Drug Administration (FDA) ruled on Avandia, its new diabetes treatment, last week. Batstone adds: "The ruling was positive and SmithKline could be looking at sales of $1.5bn to $2bn."

Start your day with The Independent, sign up for daily news emails
News
Keith Fraser says we should give Isis sympathises free flights to join Isis (AFP)
news
Life and Style
Google celebrates the 126th anniversary of the Eiffel Tower opening its doors to the public for the first time
techGoogle celebrates Paris's iconic landmark, which opened to the public 126 years ago today
News
Cleopatra the tortoise suffers from a painful disease that causes her shell to disintegrate; her new prosthetic one has been custom-made for her using 3D printing technology
newsCleopatra had been suffering from 'pyramiding'
News
people
Arts and Entertainment
Coachella and Lollapalooza festivals have both listed the selfie stick devices as “prohibited items”
music
Sport
Nigel Owens was targeted on Twitter because of his sexuality during the Six Nations finale between England and France earlier this month
rugbyReferee Nigel Owens on coming out, and homophobic Twitter abuse
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Trainee Consultant - Surrey / South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

Ashdown Group: Trainee Consultant - Surrey/ South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

Recruitment Genius: Client Services Assistant

£18000 - £20000 per annum: Recruitment Genius: A Client Services Assistant is ...

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Day In a Page

No postcode? No vote

Floating voters

How living on a houseboat meant I didn't officially 'exist'
Louis Theroux's affable Englishman routine begins to wear thin

By Reason of Insanity

Louis Theroux's affable Englishman routine begins to wear thin
Power dressing is back – but no shoulderpads!

Power dressing is back

But banish all thoughts of Eighties shoulderpads
Spanish stone-age cave paintings 'under threat' after being re-opened to the public

Spanish stone-age cave paintings in Altamira 'under threat'

Caves were re-opened to the public
'I was the bookies’ favourite to be first to leave the Cabinet'

Vince Cable interview

'I was the bookies’ favourite to be first to leave the Cabinet'
Election 2015: How many of the Government's coalition agreement promises have been kept?

Promises, promises

But how many coalition agreement pledges have been kept?
The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

The death of a Gaza fisherman

He built his own reef, and was fatally shot there by an Israeli gunboat
Saudi Arabia's airstrikes in Yemen are fuelling the Gulf's fire

Saudi airstrikes are fuelling the Gulf's fire

Arab intervention in Yemen risks entrenching Sunni-Shia divide and handing a victory to Isis, says Patrick Cockburn
Zayn Malik's departure from One Direction shows the perils of fame in the age of social media

The only direction Zayn could go

We wince at the anguish of One Direction's fans, but Malik's departure shows the perils of fame in the age of social media
Young Magician of the Year 2015: Meet the schoolgirl from Newcastle who has her heart set on being the competition's first female winner

Spells like teen spirit

A 16-year-old from Newcastle has set her heart on being the first female to win Young Magician of the Year. Jonathan Owen meets her
Jonathan Anderson: If fashion is a cycle, this young man knows just how to ride it

If fashion is a cycle, this young man knows just how to ride it

British designer Jonathan Anderson is putting his stamp on venerable house Loewe
Number plates scheme could provide a licence to offend in the land of the free

Licence to offend in the land of the free

Cash-strapped states have hit on a way of making money out of drivers that may be in collision with the First Amendment, says Rupert Cornwell
From farm to fork: Meet the Cornish fishermen, vegetable-growers and butchers causing a stir in London's top restaurants

From farm to fork in Cornwall

One man is bringing together Cornwall's most accomplished growers, fishermen and butchers with London's best chefs to put the finest, freshest produce on the plates of some of the country’s best restaurants
Robert Parker interview: The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes

Robert Parker interview

The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes
Don't believe the stereotype - or should you?

Don't believe the stereotype - or should you?

We exaggerate regional traits and turn them into jokes - and those on the receiving end are in on it too, says DJ Taylor